|
OA-specific
|
hsa01521
|
EGFR tyrosine kinase inhibitor resistance
|
7.94E-06
|
27
|
|
hsa04120
|
Ubiquitin mediated proteolysis
|
7.94E-06
|
38
|
|
hsa04068
|
FoxO signaling pathway
|
1.88E-05
|
36
|
|
hsa04012
|
ErbB signaling pathway
|
2.08E-05
|
27
|
|
hsa05215
|
Prostate cancer
|
2.59E-05
|
29
|
|
hsa04910
|
Insulin signaling pathway
|
9.18E-05
|
35
|
|
hsa04350
|
TGF-beta signaling pathway
|
1.10E-04
|
27
|
|
hsa04931
|
Insulin resistance
|
1.53E-04
|
29
|
|
hsa05205
|
Proteoglycans in cancer
|
1.53E-04
|
45
|
|
RA-specific
|
hsa04068
|
FoxO signaling pathway
|
2.39E-05
|
33
|
|
hsa04350
|
TGF-beta signaling pathway
|
3.84E-05
|
26
|
|
hsa01521
|
EGFR tyrosine kinase inhibitor resistance
|
3.84E-05
|
23
|
|
hsa04012
|
ErbB signaling pathway
|
3.84E-05
|
24
|
|
hsa04120
|
Ubiquitin mediated proteolysis
|
1.12E-04
|
31
|
|
hsa04510
|
Focal adhesion
|
1.12E-04
|
40
|
|
hsa04931
|
Insulin resistance
|
2.05E-04
|
26
|
|
hsa04151
|
PI3K-Akt signaling pathway
|
2.23E-04
|
59
|
|
hsa05215
|
Prostate cancer
|
2.23E-04
|
24
|
